Symptoms & Progression: How FSHD Affects Your Body
Last updated:
Facioscapulohumeral dystrophy (FSHD) causes asymmetric muscle weakness that progresses downward from the face to the shoulders, arms, and lower body. Beyond visible muscle changes, patients frequently experience invisible symptoms like chronic pain and severe fatigue.
Key Takeaways
- • FSHD typically causes asymmetric weakness, affecting one side of the body more severely than the other.
- • The condition follows a descending progression pattern, starting in the face and moving down to the shoulders, arms, and lower body.
- • Early-onset FSHD generally progresses faster than the classic adult-onset form and may involve hearing loss or retinal issues.
- • Invisible symptoms like chronic pain and severe fatigue are common and can significantly impact daily quality of life.
- • Occupational therapy and mobility aids like ankle-foot orthoses can help manage progressive weakness and improve daily function.
FSHD follows a pattern that is often predictable but uniquely individual. While the name itself highlights the primary areas affected—the face, shoulders, and upper arms—the condition can involve other muscle groups as it progresses. Understanding these patterns and the “invisible” symptoms that often accompany them can help you better manage your daily life. For more on how to manage these symptoms, read Building Your Care Strategy.
The Hallmark: Asymmetric Weakness
One of the most defining features of FSHD is asymmetry [1][2]. This means that weakness often affects one side of the body more than the other [2]. You might find that you can lift your left arm easily while your right arm feels heavy, or that your smile curves more on one side than the other. This asymmetry is a key “hallmark” that doctors use to distinguish FSHD from other types of muscular dystrophy [3].
The Pattern of Progression
FSHD typically follows a descending pattern, meaning it moves from the upper body downward [1].
- Face (Facio): Early signs often include difficulty whistling, drinking through a straw, or closing your eyes completely while sleeping [4].
- Shoulders (Scapulo): Weakness in the muscles that stabilize the shoulder blades (scapula) can cause them to “wing” or stick out. This makes it hard to lift your arms above your head [1].
- Upper Arms (Humeral): The biceps and triceps weaken, making lifting objects difficult [5]. Interestingly, the forearms are usually spared, meaning grip strength often remains strong even when the upper arm is weak [6].
- Trunk and Lower Body: As the condition moves down, it can affect the abdominal muscles (causing the belly to protrude) and the lower legs. This often leads to foot drop, where the toes catch while walking [1].
- Fall Risk: Because of foot drop and lower limb weakness, individuals with FSHD have a significantly higher risk of tripping and falling. An Ankle-Foot Orthosis (AFO) brace can provide critical stability [1].
While the disease is progressive, it moves slowly for most people. Roughly 20% of patients will eventually require a wheelchair for mobility [1][7].
Early-Onset vs. Classic Presentation
The speed and scope of symptoms often depend on when the disease first appears.
- Classic FSHD (Adult-Onset): Usually begins in the teens or 20s. Progression is typically slow, and symptoms are mostly limited to the muscles [8].
- Early-Onset FSHD: Defined by facial weakness before age 5 or shoulder weakness before age 10 [4]. This form tends to progress more rapidly, with about 57% of patients requiring wheelchair assistance in some cohorts [9]. It may also include systemic features (affects other organs), such as:
Underappreciated Symptoms
Beyond the visible muscle weakness, FSHD often brings “invisible” challenges that significantly impact quality of life:
- Pain and Fatigue: These are among the most common symptoms. Roughly 71% of patients experience chronic pain [12], and profound fatigue is frequently reported [13].
- Speech and Swallowing: Though usually mild, 35% of patients report difficulty with clear speech (dysarthria), and 25% to 40% report difficulty swallowing (dysphagia) [14][12]. These issues are often linked to weakness in the cheeks and facial muscles [14].
Managing Activities of Daily Living
As the disease progresses, simple tasks can become frustrating. If you lose the ability to lift your arms, an Occupational Therapist (OT) can provide specialized tools and strategies to help with Activities of Daily Living (ADLs)—such as using long-handled sponges for washing hair, dressing aids, or grabbing tools to reach high shelves. You do not have to just “live with” the frustration of daily tasks becoming harder.
Frequently Asked Questions
Why is my muscle weakness worse on one side?
What is the typical progression pattern for FSHD?
Are pain and fatigue common with FSHD?
What is the difference between classic and early-onset FSHD?
Can FSHD affect my speech and swallowing?
Questions for Your Doctor
- • Which of my muscle groups are currently showing the most significant weakness, and how does this fit into the typical FSHD progression pattern?
- • Is the pain or fatigue I'm experiencing typical for FSHD, and what strategies (physical therapy, medications) can we use to manage them?
- • Given my current level of muscle function, should I be evaluated for mild speech or swallowing issues (dysarthria/dysphagia)?
- • For early-onset cases: How often should we be screening for retinal (eye) health and hearing changes?
- • Are there specific exercises or types of physical therapy I should avoid to prevent overworking the muscles that are still strong?
Questions for You
- • Have I noticed that one side of my body (like my smile or my ability to lift an arm) is significantly weaker than the other?
- • Am I having trouble with 'invisible' symptoms like profound tiredness or chronic aching in my joints and muscles?
- • Have I noticed any subtle changes in my speech or difficulty swallowing certain types of food or liquids?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
Updating the Clinical Picture of Facioscapulohumeral Muscular Dystrophy: Ramifications for Drug Development With Potential Solutions.
Huml RA, Uspenskaya-Cadoz O, Dawson J, Slifer Z
Therapeutic innovation & regulatory science 2020; (54(1)):144-150 doi:10.1007/s43441-019-00038-w.
PMID: 32008231 - 2
A case of type 1 facioscapulohumeral muscular dystrophy (FSHD) with restrictive ventilatory defect and congestive heart failure.
Morimoto N, Morimoto M, Takahashi Y, et al.
eNeurologicalSci 2020; (21()):100284 doi:10.1016/j.ensci.2020.100284.
PMID: 33195829 - 3
Muscle MRI findings in facioscapulohumeral muscular dystrophy.
Gerevini S, Scarlato M, Maggi L, et al.
European radiology 2016; (26(3)):693-705 doi:10.1007/s00330-015-3890-1.
PMID: 26115655 - 4
A multinational study on motor function in early-onset FSHD.
Mah JK, Feng J, Jacobs MB, et al.
Neurology 2018; (90(15)):e1333-e1338 doi:10.1212/WNL.0000000000005297.
PMID: 29540582 - 5
[Research advances in limb-girdle muscular dystrophy type 2Q].
Zhang M, Lan D
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2019; (21(8)):839-844.
PMID: 31416513 - 6
Muscle MRI of facioscapulohumeral dystrophy (FSHD): A growing demand and a promising approach.
Fatehi F, Salort-Campana E, Le Troter A, et al.
Revue neurologique 2016; (172(10)):566-571 doi:10.1016/j.neurol.2016.08.002.
PMID: 27663058 - 7
Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy.
Lim KRQ, Yokota T
Frontiers in pharmacology 2021; (12()):642858 doi:10.3389/fphar.2021.642858.
PMID: 33776777 - 8
Early-Onset Infantile Facioscapulohumeral Muscular Dystrophy: A Timely Review.
Chen TH, Wu YZ, Tseng YH
International journal of molecular sciences 2020; (21(20)) doi:10.3390/ijms21207783.
PMID: 33096728 - 9
Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy.
Goselink RJM, Mul K, van Kernebeek CR, et al.
Neurology 2019; (92(4)):e378-e385 doi:10.1212/WNL.0000000000006819.
PMID: 30568007 - 10
French National Protocol for diagnosis and care of facioscapulohumeral muscular dystrophy (FSHD).
Attarian S, Beloribi-Djefaflia S, Bernard R, et al.
Journal of neurology 2024; (271(9)):5778-5803 doi:10.1007/s00415-024-12538-3.
PMID: 38955828 - 11
Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD).
Goselink RJ, Schreuder TH, Mul K, et al.
BMC neurology 2016; (16()):138 doi:10.1186/s12883-016-0664-6.
PMID: 27530735 - 12
Systemic manifestations and symptom burden of facioscapulohumeral muscular dystrophy in a referral cohort.
Kelly CR, Saw JL, Thapa P, et al.
Muscle & nerve 2022; (65(4)):415-421 doi:10.1002/mus.27493.
PMID: 35020192 - 13
Facing facial weakness: psychosocial outcomes of facial weakness and reduced facial function in facioscapulohumeral muscular dystrophy.
van de Geest-Buit WA, Rasing NB, Mul K, et al.
Disability and rehabilitation 2023; (45(15)):2507-2516 doi:10.1080/09638288.2022.2092779.
PMID: 35815498 - 14
Effects of weakness of orofacial muscles on swallowing and communication in FSHD.
Mul K, Berggren KN, Sills MY, et al.
Neurology 2019; (92(9)):e957-e963 doi:10.1212/WNL.0000000000007013.
PMID: 30804066
This page explains FSHD symptoms and progression for educational purposes only. Always consult your neurologist or healthcare team for a personalized evaluation and symptom management plan.
Stay up to date
Get notified when new research about Facioscapulohumeral dystrophy is published.
No spam. Unsubscribe anytime.